AMGEN Inc
NASDAQ: AMGN
$297.78
-$10.03 (-3.3%)
Closing Price on February 6, 2025
AMGN Articles
Thursday's top analyst upgrades, downgrades and initiations include Barrick Gold, Facebook, Halcon Resources, Qualcomm, Synchrony Financial and Texas Instruments.
Published:
Amgen reported better-than-expected first-quarter 2015 earnings Tuesday afternoon after equity markets had closed.
Published:
Last Updated:
After markets close on Tuesday, Amgen, the second-largest biotech, is scheduled to announce its first-quarter results.
Published:
Last Updated:
The March 31 short interest data have been compared with the March 13 figures, and for most of the selected biotech stocks, short interest has increased.
Published:
Jon OggIf there is one firm on Wall Street that investors have been told that they want to pay attention to during analyst upgrades and downgrades, it is Goldman Sachs. The firm has analysts who are...
Published:
DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend. Should investors should expect a big stock buyback?
Published:
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
Published:
24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen...
Published:
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
Published:
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Logically, it seems that as they stock market zooms higher, insiders who want to buy stock would wait until a pullback to add new capital.
Published:
Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a move follows Amgen.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
Published:
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.